Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex
{{output}}
Everolimus is an orally administered inhibitor of the mammalian target of rapamycin (mTOR). Everolimus (starting dosage 3.0 mg/m(2)) was associated with a significant reduction in the volume of the largest subependymal giant cell astrocytoma (SEGA) in 28 patie... ...
